Components:
Method of action:
Treatment option:
Medically reviewed by Kovalenko Svetlana Olegovna, PharmD. Last updated on 06.04.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
Inbestan 0.01%e Fumarate Syrup is indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus and lacrimation. Inbestan 0.01%e Fumarate Syrup is indicated for use in pediatric populations (age 6 years through 12) and adults (see DOSAGE AND ADMINISTRATION).
It should be noted that Inbestan 0.01%e is indicated for the relief of mild uncomplicated allergic skin manifestations of urticaria and angioedema at the 2 mg dosage level only.
DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND RESPONSE OF THE PATIENT.
Pediatric
Adults and Children 12 Years and Over
For Symptoms of Allergic Rhinitis - The starting dose is 2 teaspoonfuls (1 mgInbestan 0.01%e) twice daily. Dosage may be increased as required, but not to exceed 12 teaspoonfuls daily (6 mg Inbestan 0.01%e).
For Urticaria and Angioedema - The starting dose is 4 teaspoonfuls (2 mg Inbestan 0.01%e) twice daily, not to exceed 12 teaspoonfuls daily (6 mg Inbestan 0.01%e).
Antihistamines are contraindicated in patients hypersensitive to the drug or to other antihistamines of similar chemical structure (see PRECAUTIONS: DRUG INTERACTIONS).
Antihistamines should not be used in newborn or premature infants. Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers (see PRECAUTIONS-Nursing Mothers).
WARNINGS
Antihistamines should be used with considerable caution in patients with: narrow angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, and bladder neck obstruction.
Use with CNS Depressants
Inbestan 0.01%e has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.).
Use in Activities Requiring Mental Alertness
Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc.
Use in the Elderly (approximately 60 years or older)
Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.
PRECAUTIONS
General
Inbestan 0.01%e fumarate should be used with caution in patients with: history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease, and hypertension.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Pregnancy
Teratogenic Effects
Nursing Mothers
Although quantitative determinations of antihistaminic drugs in breast milk have not been reported, qualitative tests have documented the excretion of diphenhydramine, pyrilamine, and tripelennamine in human milk.
Because of the potential for adverse reactions in nursing infants from antihistamines, a decision should be made whether to discontinue nursing or to discontinue the drug.
Pediatric Use
The safety and efficacy of Inbestan 0.01%e Fumarate Syrup has been confirmed in the pediatric population (age 6 years through 12). Safety and dose tolerance studies have confirmed pediatric patients 6 through 11 years tolerated dosage ranges of 0.75 to 2.25 mg Inbestan 0.01%e. In pediatric patients particularly, antihistamines in overdosage may produce hallucinations, convulsions and death. Symptoms of antihistamine toxicity in pediatric patients may include fixed dilated pupils, flushed face, dry mouth, fever, excitation, hallucinations, ataxia, incoordination, athetosis, tonic-clonic convulsions, and postictal depression (see OVERDOSAGE).
Carcinogenesis, Mutagenesis, Impairment of Fertility
Pregnancy
Teratogenic Effects
Nursing Mothers
Although quantitative determinations of antihistaminic drugs in breast milk have not been reported, qualitative tests have documented the excretion of diphenhydramine, pyrilamine, and tripelennamine in human milk.
Because of the potential for adverse reactions in nursing infants from antihistamines, a decision should be made whether to discontinue nursing or to discontinue the drug.
Pediatric Use
The safety and efficacy of Inbestan 0.01%e Fumarate Syrup has been confirmed in the pediatric population (age 6 years through 12). Safety and dose tolerance studies have confirmed pediatric patients 6 through 11 years tolerated dosage ranges of 0.75 to 2.25 mg Inbestan 0.01%e. In pediatric patients particularly, antihistamines in overdosage may produce hallucinations, convulsions and death. Symptoms of antihistamine toxicity in pediatric patients may include fixed dilated pupils, flushed face, dry mouth, fever, excitation, hallucinations, ataxia, incoordination, athetosis, tonic-clonic convulsions, and postictal depression (see OVERDOSAGE).
The most frequent adverse reactions are italicized:
Nervous System
Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.
Gastrointestinal System
Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation.
Respiratory System
Thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness.
Cardiovascular System
Hypotension, headache, palpitations, tachycardia, extrasystoles.
Hematologic System
Hemolytic anemia, thrombocytopenia, agranulocytosis.
Genitourinary System
Urinary frequency, difficult urination, urinary retention, early menses.
General
Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and throat.
Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. In children, stimulation predominates initially in a syndrome which may include exclient, hallucinations, ataxia, incoordination, muscle twitching, athetosis, hyperthermia, cyanosis convulsions, tremors, and hyperreflexia followed by postictal depression and cardio-respiratory arrest. Convulsions in children may be preceded by mild depression. Dry mouth, fixed dilated pupils, flushing of the face, and fever are common. In adults, CNS depression, ranging from drowsiness to coma, is more common. The convulsant dose of antihistamines lies near the lethal dose. Convulsions indicate a poor prognosis.
In both children and adults, coma and cardiovascular collapse may occur. Deaths are reported especially in infants and children.
There is no specific therapy for acute overdosage with antihistamines. The latent period from ingestion to appearance of toxic effects is characteristically short (1/2-2 hours). General symptomatic and supportive measures should be instituted promptly and maintained for as long as necessary.
Since overdoses of other classes of drugs (i.e. tricyclic antidepressants) may also present anticholinergic symptomatology, appropriate toxicological analysis should be performed as soon as possible to identify the causative agent.
In the conscious patient, vomiting should be induced even though it may have occurred spontaneously. If vomiting cannot be induced, gastric lavage is indicated. Adequate precautions must be taken to protect against aspiration, especially in infants and children. Charcoal slurry or other suitable agents should be instilled into the stomach after vomiting or lavage. Saline cathartics or milk of magnesia may be of additional benefit.
In the unconscious patient, the airway should be secured with a cuffed endotracheal tube before attempting to evacuate the gastric spans. Intensive supportive and nursing care is indicated, as for any comatose patient.
If breathing is significantly impaired, maintenance of an adequate airway and mechanical support of respiration is the most effective means of providing adequate oxygenation.
Hypotension is an early sign of impending cardiovascular collapse and should be treated vigorously. Although general supportive measures are important, specific treatment with intravenous infusion of a vasopressor titrated to maintain adequate blood pressure may be necessary.
Do not use with CNS stimulants.
Convulsions should be controlled by careful administration of diazepam or a short-acting barbiturate, repeated as necessary. Physostigmine may also be considered for use in controlling centrally mediated convulsions.
Ice packs and cooling sponge baths, not alcohol, can aid in reducing the fever commonly seen in children. A more detailed review of antihistamine toxicology and overdose management is available in Gosselin, R.E., et. al., "Clinical Toxicology of Commercial Products."
